期刊文献+

霉酚酸钠肠溶片用于国人肾移植受者的药代动力学监测 被引量:4

Pharmacokinetics monitoring of EC-MPS in Chinese renal allograft recipients
下载PDF
导出
摘要 目的:观察服用霉酚酸钠肠溶片( EC-MPS)的国人肾移植受者血中霉酚酸( MPA)的药代动力学特征,建立简化的MPA血浆浓度—时间曲线下面积(AUC)的计算公式。方法30例肾移植受者均接受EC-MPS1.44 g/d联合环孢素、强的松的三联免疫抑制方案。采用EMIT法测服药前及服药后0.5、1、1.5、2、4、6、8、10、12 h的血浆MPA浓度(分别为C0.5、C1、C1.5、C2、C4、C6、C8、C10、C12)。采用药理学专用软件计算MPA AUC0~12 h ,并以多元逐步回归分析法得出适合国人的MPAAUC0~12h的简化计算公式。结果30例肾移植受者EC-MPS的药代动力学参数存在显著个体差异。 MPA AUC0~12 h平均值为(47.64±25.14)mg·h/L。选取2个取样时点的C1.5、C2和4个取样时点的C2、C4、C6、C8,分别得出MPA AUC的简化计算公式:AUC=27.41+0.87×C1.5+0.88×C2(r2=0.67)和AUC=3.98+2.03×C2+2.18×C4+1.91×C6+5.08×C8(r2=0.86),其对MPA AUC预测值的绝对误差分别为(28.8±24.8)%和(12.8±10.1)%;30例肾移植受者中,MPA AUC预测值误差均在MPA AUC0~12 h的±15%以内。结论服用EC-MPS的国人肾移植受者血浆中MPA药代动力学呈现较大的个体差异;得出取样点少(2个取样时点或4个取样时点)、预测效果好的MPA AUC简化计算公式。 Objective To observe the pharmacokinetics features of mycophenolic acid ( MPA) in Chinese renal al-lograft recipients who took Myfortic ( EC-MPS) and to establish a calculation for the abbreviated MPA area under the curve (AUC) of plasma concentration and time .Methods Thirty renal-transplant recipients were treated with EC-MPS (1.44 g/d) in combination with cyclosporine ( CsA) and prednisone ( Pred) .Plasma MPA concentrations were determined by E-MIT method at pre-medication, 0.5, 1, 1.5, 2, 4, 6, 8, 10 and 12 hours (C0.5,C1,C1.5,C2,C4,C6,C8,C10 and C12) af-ter oral administration .The MPA AUC0-12 h were calculated by using the trapezoidal rule and the abbreviated MPA AUC model equation fitted to 30 MPA AUC0-12 h profiles was generated by the multiple regression analysis .Results The phar-macokinetics of EC-MPS in 30 renal-transplant recipients manifested great inter-patient difference . The mean MPA AUC0-12 h was (47.64 ±25.14) mg· h/L.We selected C1.5, and C2 at two different time points and C2, C4, C6 and C8 at four different time points.Then, the abbreviated MPA AUC model equations were recommended:AUC=27.41+0.87 ×C1.5 +0.88 ×C2(r2 =0.67), or AUC=3.98+2.03 ×C2 +2.18 ×C4 +1.91 ×C6 +5.08 ×C8(r2 =0.86);the abso-lute prediction error was (28.8 ±24.8)%and (12.8 ±10.1)%, respectively.In 30 recipients, the absolute prediction error between estimated MPA AUC and full MPAAUC 0-12 h was within ±15%.Conclusions EC-MPS pharmacokinetics in Chinese renal allograft recipients manifests a substantial inter-individual variability .We get the MPA AUC simplified calcu-lation formula, which needs less sampling point and has good predictive effect .
出处 《山东医药》 CAS 北大核心 2015年第18期10-13,共4页 Shandong Medical Journal
基金 卫生部国际交流与合作中心2012年度器官移植科研项目(IHECC08-201212)
关键词 肾移植 霉酚酸 药代动力学 中国人 kidney transplantation mycophenolic acid pharmacokinetics Chinese
  • 相关文献

参考文献8

  • 1Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European mycophenolate mofetil cooperative study group[ Jl. Lan- cet, 1995,345 ( 8961 ) : 1321-1325.
  • 2Ranganathan D, John GT, Healy H, et al. A protocol for the phar- macokinetics of enteric coated mycophenolate sodium in lupus ne- phritis ( poemslun ) : An open-label, randomised controlled trial [J]. BMJOpen, 2013,3(8).
  • 3Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacody- namics of mycophenolate in solid organ transplant recipients [ J 1. Clin Pharmacokinet, 2007,46( 1 ) : 13-58.
  • 4Hale MD, Nicholls A J, Bullingham RE, et al. The pharmacokinetic- phannacodynamic relationship for mycophenolate mofetil in renal transplantation[J~. Clin Phannacol Ther, 1998,64(6) :672-683.
  • 5Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement [ J 1. Lancet, 1986,1 (8476) :307-310.
  • 6Touw DJ, Neef C, Thomson AH, et al. Cost-effectiveness of thera- peutic drug monitoring: A systematic review [ J 1- Ther Drug Monit, 2005,27 ( 1 ) : 10-17.
  • 7Meiser BM, Pfeiffer M, Schmidt D, et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac trans- plantation: Importance of mycophenolic acid therapeutic drug mo- nitoring[J]. JHeart Lung Transplant, 1999,18(2) :143-149.
  • 8Mohammadpour AH, Nazemian F, Abtahi B, et al. Estimation of abbreviated mycophenolic acid area under the concentration-time curve during early posttransplant period by limited sampling strate- gy[J]. Transplant Proc, 2008,40(10) :3668-3672.

同被引文献37

  • 1焦正,钟建泳,沈杰,梁惠琪,张明,郁韵秋,钟明康.有限采样法对麦考酚酸进行血药浓度监测[J].中国新药与临床杂志,2006,25(3):172-175. 被引量:9
  • 2周佩军,徐达,王祥慧,余自成,赵菊平.肾移植受者霉酚酸治疗药物监测[J].上海交通大学学报(医学版),2006,26(6):680-684. 被引量:11
  • 3沈兵,谭建明,焦正,龚华,刘志宏,秦燕,刘永,包尔敦,范昱.有限采样法监测肾移植受者的血霉酚酸浓度[J].中华器官移植杂志,2006,27(7):414-417. 被引量:7
  • 4王海燕.肾脏病学[M].3版.北京:人民卫生出版社,2008:8262.
  • 5国家药品不良反应监测中心.常见严重药品不良反应技术规范及评价标准[S], 2011 -03 -29.
  • 6KDIGO clinical practice guideline for the care of kidney trans- plant recipients[J]. Am J Transplant,2009, 9(Suppl 3): s1- s157.
  • 7Staatz CE, Tett SE. Clinical pharrnacokinetics and pharmaeo- dynamics of mycophenolate in solid organ transplant recipients [J]. Clin Pharmacokinet,2007,46(1):13-58.
  • 8Land W, Vincenti F. Toxicity-sparing protocols using myco- phenolate mofetil in renal transplantation [ J]. Transplanta- tion, 2005,80 (2 Suppl) s221-s234.
  • 9Le Meura Y, Biiehlerb M, Thierryc A, et al. Individualized Mycophenolate Mofetil dosing based on drug exposure signifi- cantly improves patient outcomes after renal transplantation [J]. Am J Transplant, 2007,7,2496-2503.
  • 10Gastona RS, Kaplanb B, Shahc T,et al. Fixed or controlled- dose mycophenolate mofetil with standard- or reduced-dose cal- cineurin inhibitors: the opticept trial [J]. Am J Transplant, 2009,9:1607-1619.

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部